CHICAGO — Slow release of concentrated ranibizumab via a surgically implanted port delivery system demonstrated durable disease control in patients with neovascular age-related macular degeneration.
The Ladder trial is an ongoing dose-ranging four-arm phase 2 study designed to characterize the durability and safety of the port delivery system at three different concentrations of ranibizumab, compared with one arm of monthly intravitreal injections of ranibizumab. Primary endpoint was time to first required refill.
“It was the high concentration 100 mg/mL device arm that performed
Uncategorized